PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AS DIAGNOSTIC BIOMARKER IN PROSTATE CANCER

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2022-01-11
Lucky Frannata Indrawarman Soeroharjo Raden Danarto Didik Setyo Heriyanto

Abstract

Objective: This study aimed to compare PSMA expression in both prostate cancer and benign prostate disease. Material & Methods: PSMA antigen expression was examined using polymerase chain reaction (PCR), twenty samples from each prostate cancer and benign prostate group were examined at the Department of Pathology Anatomy, Sardjito General Hospital. The data was analyzed using version 21 of SPSS.  Results: The mean PSMA gene expression in benign groups was 13.49 [95% CI: 11.27 – 15.72] and the mean PSMA gene expression in the malignant group was: 25.14 [95% CI: 20.95-29.33], the p-value was <0.01. Using an independent T-test analysis, we found that the increase in PSMA gene expression in the prostate cancer group was statistically significant. Conclusion: The expression of the PSMA gene was correlated with prostate cancer. Increased PSMA gene expression in prostate tissue could be used as a biomarker to diagnose prostate cancer.


##plugins.themes.bootstrap3.article.details##

Keywords

PSMA, prostate cancer, PCR, gene expression

References

Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pacific J Cancer Prev. 2014; 15(22): 9575-9578.

Castillejos-molina RA, Gabilondo-navarro FB. Castillejos-Molina. Prostate cancer. Salud Publica Mex. 2016; 58(2): 279-284.

Jakobsen NA, Hamdy FC, Bryant RJ. Novel biomarkers for the detection of prostate cancer. J Clin Urol. 2016; 9(2_suppl): 3-10.

Wright GL, Haley C, Beckett M Lou, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol Semin Orig Investig. 1995; 1(1): 18-28.

Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004; 6 Suppl 10(Figure 1): S13-8.

Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Van Den Eeden SK. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Urology. Published online 2020: 1-9.

Ristau BT, O’Keefe DS, Bacich DJ. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol Oncol Semin Orig Investig. 2014; 32(3): 272-279.

Demirkol MO, Acar Ö, Uçar B, Ramazanoʇlu SR, Saʇlican Y, Esen TDLDAL. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015; 75(7): 748-757.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University